Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

BRAINMOS Brain Mosaicism Matters: Organoids in focus to unveil mechanisms in epileptogenic cortical malformations

Coordinator
Institut Du Cerveau Et De La Moelle Epiniere, France
Runs
1 April 2024 to 31 March 2026
Status
Running
EU funding
€196k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101152145

What the project is doing

In the project's own words, from its summary on CORDIS.

Epilepsy, a global neurological disorder affecting around 70 million people, poses a significant medical challenge, with one-third of patients facing drug-resistant epilepsy. Cortical malformations such as focal cortical dysplasia type II (FCDII) are associated with pediatric drug-resistant epilepsy for which surgical intervention serves as the main therapeutic approach for seizure control. FCDII is marked by cortical dyslamination and the presence of abnormal cytomegalic cells.

Recent findings show that FCDII results from brain mosaicism due to postzygotic mutations in genes of the mTOR pathway, which produces excessive activation of the pathway. Nevertheless, as the human surgical FCDII samples represent an advanced disease stage, we poorly understand its developmental origin and mechanisms. Moreover, the link between mTOR activation and epileptogenesis remains unclear. To address these critical knowledge gaps, a disease-relevant FCDII model is needed.

For the preservation of human-specific features, I will use a mosaic cortical organoid model that expresses an inducible MTOR-S2215F mutant construct to reflect the somatic nature of FCDII. Induction of the mutation at different time points will shed light on the specific time frame during which mutations occur in FCDII patients and enable us to generate a preclinical model replicating an FCDII-like phenotype. Next, I will perform single-cell transcriptomic profiling at various developmental stages to uncover the cellular and molecular mechanisms behind FCDII development.

Finally, the neuronal network activity of mosaic FCDII cortical organoids will be characterized, focusing on identifying the primary drivers of epileptiform activity among mutant cytomegalic or non-mutant nearby cells. In brief, this preclinical FCDII model has the potential to unveil novel developmental mechanisms, offer new non-invasive avenues for treating FCDII patients with drug-resistant epilepsy, and boost my career trajectory in the field.

Topics

Who is involved

OrganisationCityCountryRole
Institut Du Cerveau Et De La Moelle EpiniereParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI